Celldex Therapeutics, Inc. Logo

Email this page: News Release

Data Safety and Monitoring Board Recommends Celldex's Phase 3 Study of RINTEGA® (rindopepimut) in Newly Diagnosed Glioblastoma be Discontinued as it is Unlikely to Meet Primary Overall Survival Endpoint in Patients with Minimal Residual Disease

 

Separate multiple addresses with commas. Maximum 200 characters.
 
 


These email addresses will be used to email the page on your behalf and will not be used by Celldex Therapeutics, Inc. for any marketing purposes.

Send:       


 
This helps Celldex Therapeutics, Inc. prevent automated submissions.